Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of teprotumumab in active thyroid eye disease
2014-000113-31Phase 2Completed
- Sponsor
- River Vision Development Corp.
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Graves Orbitopathy (GO) and Graves' ophthalmopathy (TED) comparing Teprotumumab with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Mar 2014; status: completed.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2014-000113-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000113-31.